NOT KNOWN FACTUAL STATEMENTS ABOUT CX-6258 HYDROCHLORIDE

In summary, currently available preclinical and medical data support the development of GS-0976 as Element of combination therapy for NASH to lessen hepatic steatosis, lipotoxicity, as well as their downstream deleterious results.In clients with bridging fibrosis and cirrhosis, 48 weeks of cilofexor/firsocostat was perfectly tolerated, brought abo